Epidemiology, risk factors and genotypes of HBV in HIV-infected patients in the northeast region of Colombia: High prevalence of occult hepatitis B and F3 subgenotype dominance

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Bautista Amorocho, Henry ^a   Castellanos Domínguez, Yeny Zulay ^a   Rodríguez Villamizar, Laura Andrea ^b   Velandia Cruz, Sindi Alejandra ^a   Becerra Peña, Jeysson Andrey ^a   Farfán García, Ana Elvira ^a  

^a UNIVERSIDAD DE SANTANDER   (Colombia)

^b UNIVERSIDAD INDUSTRIAL DE SANTANDER   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CHILD; COLOMBIA; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; ENDEMIC DISEASE; FEMALE; GENE MUTATION; GENOTYPE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIXED INFECTION; MOLECULAR PHYLOGENY; OCCULT HEPATITIS B; POLYMERASE CHAIN REACTION; RISK FACTOR; SEQUENCE ANALYSIS; VIRUS GENE; YOUNG ADULT; COMPLICATION; CROSS-SECTIONAL STUDY; EPIDEMIOLOGY; GENETICS; HEPATITIS B VIRUS; MOLECULAR GENETICS; PREVALENCE; VIROLOGY;

HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

ADULT; COLOMBIA; CROSS-SECTIONAL STUDIES; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PREVALENCE; RISK FACTORS;

EID: 84918792977     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114272     Document Type: Article

References (50)

1. Rustgi VK, Hoofnagle JH, Gerin GL, Gelmann EP, Reichert CM, et al. (1984) Hepatitis B infection in the acquired immunodeficiency syndrome. Ann Intern Med 101:795-797.
2. Global report: UNAIDS report on the global AIDS epidemic (Nov 2013). Available: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120-UNAIDS-Global-Report-2012-en.pdf. Accessed 2014 August 11.
3. Alter MJ (2006) Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 44:S6-9.
4. Martínez E, Milinkovic A, Buira E, de Lazzari E, León A, et al. (2007) Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area. HIV Med 8:251-8.
5. Martín-Carbonero L, Teixeira T, Poveda E, Plaza Z, Vispo E, et al. (2011) Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. AIDS 25:73-9.
6. Chun HM, Roediger MP, Hullsiek KH, Thio CL, Agan BK, et al. (2012) Infectious Disease Clinical Research Program HIV Working Group. Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. J Infect Dis 205:185-93.
7. Liang SH, Chen TJ, Lee SS, Tseng FC, Huang CK, et al. (2010) Risk factors of isolated antibody against core antigen of hepatitis B virus: association with HIV infection and age but not hepatitis C virus infection. J Acquir Immune Defic Syndr 54:122-8.
8. Kew MC (2010) Hepatocellular carcinoma in African Blacks: Recent progress in etiology and pathogenesis. World J Hepatol 2:65-73.
9. Day SL, Odem-Davis K, Mandaliya KN, Jerome KR, Cook L, et al. (2013) Prevalence, Clinical and Virologic Outcomes of Hepatitis B Virus Co-Infection in HIV-1 Positive Kenyan Women on Antiretroviral Therapy. PLoS One 8: e59346.
10. Badur S, Akgün A (2001) Diagnosis of hepatitis B infections and monitoring of treatment. J Clin Virol 21:229-37.
11. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, et al. (2008) Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 49:652-7.
12. Zobeiri M (2013) Occult Hepatitis B: Clinical Viewpoint and Management. Hepat Res Treat 259148:1-7.
13. Schmeltzer P, Sherman KE (2010) Occult hepatitis B: clinical implications and treatment decisions. Dig Dis Sci 55:3328-35.
14. Raimondo G, Caccamo G, Filomia R, Pollicino T (2013) Occult HBV infection. Semin Immunopathol 35:39-52.
15. Samal J, Kandpal M, Vivekanandan P (2012) Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev 25:142-63.
16. Shi Y, Wu YH, Wu W, Zhang WJ, Yang J, et al. (2012) Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis. Liver Int 32:231-40.
17. Ikeda K, Kobayashi M, Someya T, Saitoh S, Hosaka T, et al. (2009) Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: a cohort study. J Viral Hepat 16:437-43.
18. Te HS, Jensen DM (2010) Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 14:1-21.
19. Alvarado-Mora MV, Fernandez MF, Gomes-Gouvêa MS, de Azevedo Neto RS, Carrilho FJ, et al. (2011) Hepatitis B (HBV), hepatitis C (HCV) and hepatitis delta (HDV) viruses in the Colombian population - how is the epidemiological situation? PLoS One 296:e18888.
20. Otero JA, Uribe JC, Hormiga CM (2013) Perfil de morbilidad y mortalidad de Santander. Revista del Observatorio de Salud Pública de Santander 2:3-54. Available: http://web.saludsantander.gov.co/index.php?option=com-docman&task=doc-download&gid=500&Itemid=21 Accessed 2014 Jun 13.
21. Ministerio de Salud y Protección Social. Instituto Nacional de Salud (11 Jun 2014). Protocolo de vigilancia en salud pública. Hepatitis B, C y coinfección hepatitis B-Delta. Available: http://www.ins.gov.co/lineas-de-accion/subdireccion-vigilancia/sivigila/protocolos%20sivigila/pro%20hepatitis%20b%20c%20y%20delta.pdf Accessed 2014 August 11.
22. Saitou N, Nei M (1987) The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 4:406-425.
23. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S (2013) MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol Evol 30:2725-9.
24. Kimura M (1980) A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol 16:111-120.
25. Avellon A, Echevarria JM (2006) Frequency of hepatitis B virus 'a' determinant variants unselected Spanish chronic carriers. J Med Virol 78:24-36.
26. World Health Organization (March, 2014). To the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection recommendations for a public health approach supplement. Available: http://www.who.int/hiv/pub/guidelines/arv2013/arvs2013upplement-march2014/en/Accessed 2014 August 11.
27. Torres-Baranda R, Bastidas-Ramírez BE, Maldonado-González M, Sánchez-Orozco LV, Vázquez-Vals E, et al. (2006) Occult hepatitis B in Mexican patients with HIV, an analysis using nested polymerase chain reaction. Ann Hepatol 5:34-40.
28. Attia KA, Eholié S, Messou E, Danel C, Polneau S, et al. (2012) Prevalence and virological profiles of hepatitis B infection in human immunodeficiency virus patients. World J Hepatol 4:218-23.
29. Mphahlele M, Lukhwareni A, Burnett R, Moropeng L, Ngobeni J (2006) High risk of ocullt hepatitis B virus infection in HIV- positive patients from South Africa. J Clin Virol 35:14-20.
30. Tyson GL, Kramer JR, Duan Z, Davila JA, Richardson PA, et al. (2013) Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology 58:538-45.
31. Mendes-Corrêa MC, Barone AA, Cavalheiro N, Tengan FM, Guastini C (2000) Prevalence of hepatitis B and C in the sera of patients with HIV infection in São Paulo, Brazil. Rev Inst MedTrop Sao Paulo 42:81-5.
32. Souza MG, Passos ADC, Machado AA, Figueiredo JFC, Esmeraldino LE (2004) Coinfecc¸ão HIV e vírus da hepatite B: prevalência e fatores de risco. Rev Soc Bras Med Trop 37:391-5.
33. Marchesini AM, Prá-Baldi ZP, Mesquita F, Bueno R, Buchalla CM (2007) Hepatitis B and C among injecting drug users living with HIV in São Paulo, Brazil. Rev Saude Publ 41:57-63.
34. Braga WSM, Castilho MC, Santos ICV, Moura MAS, Segurado AC (2006) Low prevalence of hepatitis B virus, hepatitis D virus and hepatitis C virus among patients with human immunodeficiency virus or acquired immunodeficiency syndrome in the Brazilian Amazon basin. Rev Soc Bras Med Trop 39:519-22.
35. De Almeida Pereira RAR, Mussi ADH, Silva VCA, Souto FJD (2006) Hepatitis B virus infection in HIV-positive population in Brazil: results of survey in the state of Mato Grosso and acomparative analysis with other regions of Brazil. BMC Infect Dis 6:1-7.
36. Hoyos-Orrego A, Massaro-Ceballos M, Ospina-Ospina M, Gómez-Builes C, Vanegas-Arroyave N, et al. (2006) Serological markers and risk factors for hepatitis B and C viruses in patients infected with human immunodeficiency virus. Rev Inst Med Trop Sao Paulo 48:321-6.
37. Gupta S, Singh S (2010) Occult hepatitis B virus infection in ART-naïve HIV-infected patients seen at a tertiary care centre in north India. BMC Infect. Dis 10:53.
38. Lo Re V 3rd, Frank I, Gross R, Dockter J, Linnen JM, et al. (2007) Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients. J Acquir Immune Defic Syndr 44:315-20.
39. Sucupira MV, Mello FC, Santos EA, Niel C, Rolla VC, et al. (2006) Patterns of hepatitis B virus infection in Brazilian human immunodeficiency virus infected patients: high prevalence of occult infection and low frequency of lamivudine resistant mutations. Mem Inst Oswaldo Cruz 101:655-60.
40. Quarleri J, Moretti F, Bouzas MB, Laufer N, Carrillo MG, et al. (2007) Hepatitis B virus genotype distribution and its lamivudine-resistant mutants in HIV-coinfected patients with chronic and occult hepatitis B. AIDS Res Hum Retroviruses23:525-31.
41. Kwei K, Tang X, Lok AS, Sureau C, Garcia T, et al. (2013) Impaired Virion Secretion by Hepatitis B Virus Immune Escape Mutants and Its Rescue by Wild-Type Envelope Proteins or a Second-Site Mutation. J Virol 87:2352.
42. Moradi A, Zhand S, Ghaemi A, Javid N, Tabarraei A (2012) Mutations in the S gene region of hepatitis B virus genotype D in Golestan Province-Iran. Virus Genes 44:382-7.
43. Pal A, Panigrahi R, Biswas A, Datta S, Sarkar N, et al. (2013) Influence of HIV-associated degree of immune suppression on molecular heterogeneity of hepatitis B virus among HIV co-infected patients. Virology 436:134-42.
44. Opaleye OO, Oluremi AS, Atiba AB, Adewumi MO, Mabayoje OV, et al. (2014) Occult Hepatitis B Virus Infection among HIV Positive Patients in Nigeria. J Trop Med 2014:796121.
45. Zahn A, Li C, Danso K, Candotti D, Owusu-Ofori S, et al. (2008) Molecular characterization of occult hepatitis B virus in genotype E-infected subjects. J Gen Virol 89:409-18.
46. Awerkiew S, Däumer M, Reiser M, Wend UC, Pfister H, et al. (2006) Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient. J Clin Virol 38:83-86.
47. Cohen Stuart JW, Velema M, Schuurman R, Boucher CA, Hoepelman AI (2009) Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. J Med Virol 81:441-5.
48. Rodríguez L, Mesa FC, Aragón U, Díaz B, Rivero J (2000) Hepatitis B virus exposure in human immunodeficiency virus seropositive cuban patients. Mem Inst Oswaldo Cruz 95:243-5.
49. Nebbia G, Garcia-Diaz A, Ayliffe U, Smith C, Dervisevic S, et al. (2007) Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons. J Med Virol 79:1464-1471.
50. Alvarado Mora MV, Romano CM, Gomes-Gouvêa MS, Gutierrez MF, Botelho L, et al. (2011) Molecular characterization of the Hepatitis B virus genotypes in Colombia: a Bayesian inference on the genotype F. Infect Genet Evol11:103-8.